OpenAI's GPT-Rosalind agents surface new drug discovery lead for neurodegenerative disease
OpenAI · x · 2026-11-21
OpenAI, working with PerturbAI and Scripps Research, detailed a concrete output from GPT-Rosalind in drug discovery.
- Case: DCTN1 is linked to Perry syndrome, a rare neurodegenerative disorder. In mouse-brain data, disrupting it upregulated genes involved in cholesterol synthesis. GPT-Rosalind proposed a testable mechanism: cholesterol may not be reaching where neurons need it.
- Method: Thousands of GPT-Rosalind agents worked in parallel, connecting gene-expression results across millions of cells, giving scientists a specific mechanism to test and a potential direction for new treatments.
A representative AI-for-Science case where models generate actionable drug discovery hypotheses.
More from Companies & People
- Gary Marcus maps the AI bubble's 'Five Stages of Generative AI Grief', from denial to quantum — GaryMarcus · 2026-11-21
- Wuzhen Summit highlights open-source models, industrial AI and robots as China's key AI priorities — nordicinst · 2026-11-21
- Cognition is building a customer storytelling team, calling it a top GTM lever — igarciacamargo · 2026-11-21
- Babylon Bee Spoofs Anthropic IPO: 'Invest in the Apocalypse for $83 a Share' — DKokotajlo · 2026-11-21
- Always on: how twenty-something AI founders race a closing window — ypatil125 · 2026-11-21
- Investor: the AI bubble is a dozen zero-revenue neolabs, growth is real — ziv_ravid · 2026-11-21